

31 July 2018

Dear

Re: Request for information under the Freedom of Information Act 2000

Ref no: CAS-03594-Z0N2N5-CC (NHS Cannock Chase CCG)

CAS-03594-Z0N2N5-SAS (NHS Stafford and Surrounds CCG)

CAS-03594-Z0N2N5-SE (NHS South East Staffordshire and Seisdon Peninsula CCG)

CAS-03594-Z0N2N5-ES (NHS East Staffordshire CCG)

CAS-03594-Z0N2N5-SOT (NHS Stoke on Trent CCG)

Thank you for your correspondence dated 19 July 2018 making a request under the Freedom of Information Act 2000 for information which may be held by NHS Cannock Chase Clinical Commissioning Group (CCG), NHS East Staffordshire CCG, NHS Stafford and Surrounds CCG, NHS Stoke-on-Trent CCG and NHS South East Staffordshire and Seisdon Peninsula CCG.

You requested the following information and our response is detailed below:

Cannock Chase CCG, Stafford and Surrounds CCG, South East Staffordshire and Seisdon Peninsula CCG and East Staffordshire CCG

With respect to the following questions, please provide answers for any decisions made since 1 January 2016.

1. Please identify and state the name of any formulary group that your CCG was part of in 2016? This may include one or more of: a joint formulary committee, area formulary committee or equivalent formulary.

The South Staffordshire Area Prescribing Committee made the decision following a CCG Medicines Optimisation Group meeting. This covers the following CCG's - Cannock Chase CCG, East Staffordshire CCG, South East Staffordshire & Seisdon Peninsula CCG and Stafford & Surrounds CCG.

2. On what date was Qdem's 7-day buprenorphine transdermal patch with the product name Butec submitted to any formulary group identified in question "1" above for consideration and approval as to whether it should be included on the respective drug formulary?

It was discussed at the Medicines Optimisation Committee in April 2016 and ratified by the Area Prescribing Group in June 2016.

3. Where Butec has been added to your CCG's drugs formulary or another formulary identified in question "1", please provide any minutes that evidence what decisions were made in relation to whether to approve or reject Butec's application.

Please see the attached documents.

4. On what date was Butec first added to your CCG's drug formulary (adopting the relevant formulary identities listed above)?

◆ We are honest, accessible and we listen ◆ Quality is our day job ◆ We innovate and deliver ◆ Care and respect for all

Cannock Chase CCG Chair: Dr Mo Huda **East Staffordshire CCG Chair:** Dr Charles Pidsley **North Staffordshire CCG Chair:** Dr Alison Bradley **Stoke on Trent CCG Chair:** Dr Ruth Chambers **Stafford and Surrounds CCG Chair:** Dr Paddy Hannigan **South East Staffordshire and Seisdon Peninsula CCG Chair:** Dr Shammy Noor **Accountable Officer:** Marcus Warnes

April 2016

5. Assuming the response to question “3” is positive, has any other branded generic 7-day buprenorphine transdermal patch subsequently been added, or replaced Butec on your CCG’s drug formulary? Please indicate the date on which this occurred. If the answer to this question is positive, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject an subsequent supplier’s branded generic 7-day Buprenorphine transdermal patch application.

No further discussions have been had in South Staffordshire on buprenorphine patches since Butec was added in 2016.

6. Please provide a copy of any guidance your CCG possessed in 2016 that established the process by which a new drug would be considered for addition to your CCG’s drug formulary (again, adopting the relevant formulary identities listed in question “1”).

No formal guidance in place.

7. Please provide any other minutes recorded by your CCG that evidence what decisions were made by your CCG’s medicines management committee or other equivalent committee at CCG level to select a preferred branded generic 7-day Buprenorphine transdermal patch.

All applicable minutes are attached.

Stoke on Trent CCG

With respect to the following questions, please provide answers for any decisions made since 1 January 2016.

1. Please identify and state the name of any formulary group that your CCG was part of in 2016? This may include one or more of: a joint formulary committee, area formulary committee or equivalent formulary.

**North Staffordshire Area Prescribing Committee
New Medicines Committee**

2. On what date was Qdem’s 7-day buprenorphine transdermal patch with the product name Butec submitted to any formulary group identified in question “1” above for consideration and approval as to whether it should be included on the respective drug formulary?

N/A

3. Where Butec has been added to your CCG’s drugs formulary or another formulary identified in question “1”, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject Butec’s application.

Buprenorphine patch appears in the joint formulary without specific branded generic medicines recommended.

4. On what date was Butec first added to your CCG’s drug formulary (adopting the relevant formulary identities listed above)?

N/A

◆ We are honest, accessible and we listen ◆ Quality is our day job ◆ We innovate and deliver ◆ Care and respect for all

Cannock Chase CCG Chair: Dr Mo Huda **East Staffordshire CCG Chair:** Dr Charles Pidsley **North Staffordshire CCG Chair:** Dr Alison Bradley **Stoke on Trent CCG Chair:** Dr Ruth Chambers **Stafford and Surrounds CCG Chair:** Dr Paddy Hannigan **South East Staffordshire and Seisdon Peninsula CCG Chair:** Dr Shammy Noor **Accountable Officer:** Marcus Warnes

5. Assuming the response to question “3” is positive, has any other branded generic 7-day buprenorphine transdermal patch subsequently been added, or replaced Butec on your CCG’s drug formulary? Please indicate the date on which this occurred. If the answer to this question is positive, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject an subsequent supplier’s branded generic 7-day Buprenorphine transdermal patch application.

No formal guidance is currently in place.

6. Please provide a copy of any guidance your CCG possessed in 2016 that established the process by which a new drug would be considered for addition to your CCG’s drug formulary (again, adopting the relevant formulary identities listed in question “1”).

The New Medicines Committee process is managed by the acute Provider Trust

7. Please provide any other minutes recorded by your CCG that evidence what decisions were made by your CCG’s medicines management committee or other equivalent committee at CCG level to select a preferred branded generic 7-day Buprenorphine transdermal patch.

Not one preferred brand at CCG level, for negotiation with each general practice.

Right of appeal

Should you require any further information or clarification regarding this response, or do not feel that your request has been answered as you would expect, please contact the FOI team to discuss. However, if you remain dissatisfied with the service you have received in relation to your request and wish to request a review of our decision, this can be formally requested in writing and must be within a reasonable period of time (two calendar months) from the date this response was issued

Initially you should write to the freedom of information officer, either by email on MLCSU.FOITeam@nhs.net or post to Jubilee House, Lancashire Business Park, Leyland, PR26 6TR, specifying why you feel you have been wrongly denied access to the information requested. The freedom of information team will make sure your request is investigated by an independent reviewer who was not involved in the original consideration of your request and a written response will be provided within 20 working days.

If you are not content with the outcome of your internal review, you may apply directly to the Information Commissioners Office (ICO) for a decision. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by NHS Cannock Chase CCG, NHS East Staffordshire CCG, NHS Stafford and Surrounds CCG, NHS Stoke on Trent CCG and NHS South East Staffordshire and Seisdon Peninsula. The ICO can be contacted at:

Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF
www.ico.gov.uk

Copyright and the Re-use of Public Sector Information Regulations

Most of the information that we provide in response to Freedom of Information Act 2000 requests will be subject to copyright protection. In most cases the copyright will be owned by NHS Cannock Chase CCG, NHS East Staffordshire CCG, NHS Stafford and Surrounds CCG, NHS Stoke on Trent CCG and NHS South East Staffordshire and Seisdon Peninsula. The copyright in other information may be owned by another person or organisation, as indicated in the information itself.

You are free to use any information supplied for your own use, including for non-commercial research purposes. The information may also be used for the purposes of news reporting. However, any other

◆ **We are honest, accessible and we listen** ◆ **Quality is our day job** ◆ **We innovate and deliver** ◆ **Care and respect for all**

Cannock Chase CCG Chair: Dr Mo Huda **East Staffordshire CCG Chair:** Dr Charles Pidsley **North Staffordshire CCG Chair:** Dr Alison Bradley **Stoke on Trent CCG Chair:** Dr Ruth Chambers **Stafford and Surrounds CCG Chair:** Dr Paddy Hannigan **South East Staffordshire and Seisdon Peninsula CCG Chair:** Dr Shammy Noor **Accountable Officer:** Marcus Warnes

type of re-use, for example, by publishing the information or issuing copies to the public will require the permission of the copyright owner. For information where the copyright is owned by NHS Cannock Chase CCG, NHS East Staffordshire CCG, NHS Stafford and Surrounds CCG, NHS Stoke on Trent CCG and NHS South East Staffordshire and Seisdon Peninsula CCG please submit a request in writing stating:

- Name and address of applicant requiring permission for re-use of the information.
- Full details of the document/information required for re-use sufficient for NHS Cannock Chase CCG, NHS East Staffordshire CCG, NHS Stafford and Surrounds CCG, NHS Stoke on Trent CCG and NHS South East Staffordshire and Seisdon Peninsula CCG to identify it.
- The purpose for which the document/information is to be re-used.

For information where the copyright is owned by another person or organisation, you must apply to the copyright owner to obtain their permission. However, if you require more information on copyright please see the ICO guidance which can be accessed via the following link:

<https://ico.org.uk/media/for-organisations/documents/1151/datasets-foi-guidance.pdf>

Yours sincerely



Sally Young
Director of Corporate Services, Governance and Communications

NHS Cannock Chase CCG
NHS East Staffordshire CCG
NHS North Staffordshire CCG
NHS South East Staffordshire and Seisdon Peninsula CCG
NHS Stafford and Surrounds CCG
NHS Stoke-on-Trent CCG

◆ We are honest, accessible and we listen ◆ Quality is our day job ◆ We innovate and deliver ◆ Care and respect for all

Cannock Chase CCG Chair: Dr Mo Huda **East Staffordshire CCG Chair:** Dr Charles Pidsley **North Staffordshire CCG Chair:** Dr Alison Bradley **Stoke on Trent CCG Chair:** Dr Ruth Chambers **Stafford and Surrounds CCG Chair:** Dr Paddy Hannigan **South East Staffordshire and Seisdon Peninsula CCG Chair:** Dr Shabby Noor **Accountable Officer:** Marcus Warnes